当前位置: X-MOL 学术Hum. Gene Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses.
Human Gene Therapy ( IF 4.2 ) Pub Date : 2020-10-16 , DOI: 10.1089/hum.2020.045
Lea Krutzke 1 , Ellen Allmendinger 1 , Katja Hirt 1 , Stefan Kochanek 1
Affiliation  

Oncolytic viruses are promising anticancer agents; however, regarding their clinical efficacy, there is still significant scope for improvement. Preclinical in vivo evaluation of oncolytic viruses is mainly based on syngeneic or xenograft tumor models in mice, which is labor-intensive and time-consuming. Currently, a large proportion of developmental work in the research field of oncolytic viruses is directed toward overcoming cellular and noncellular barriers to achieve improved virus delivery to primary tumors and metastases. To evaluate the large number of genetically or chemically modified viruses regarding tumor delivery and biodistribution patterns, it would be valuable to have an in vivo model available that would allow easy screening experiments, that is of higher complexity than monoclonal cell lines, and that could be used as a platform method before confirmatory studies in small and large animals. Based on our data, we believe that the chicken chorioallantoic membrane (CAM) assay is a quick and low-cost high-throughput tumor model system for the in vivo analysis of oncolytic viruses. Here we describe the establishment, careful characterization, and optimization of the CAM model as an in vivo model for the evaluation of oncolytic viruses. We have used human adenovirus type 5 (HAdV-5) as an example for validation but are confident that the model can be used as a test system for replicating viruses of many different virus families. We show that the CAM tumor model enables intratumoral and intravenous virus administration and is a feasible and conclusive model for the analysis of relevant virus–host interactions, biodistribution patterns, and tumor-targeting profiles.

中文翻译:

用于评估溶瘤病毒的绒毛膜尿囊膜肿瘤模型。

溶瘤病毒是很有前途的抗癌剂。然而,就其临床疗效而言,仍有很大的改进空间。溶瘤病毒的临床前体内评估主要基于小鼠的同基因或异种移植肿瘤模型,这是劳动密集型和耗时的。目前,溶瘤病毒研究领域的大部分开发工作都针对克服细胞和非细胞障碍,以实现更好的病毒向原发肿瘤和转移瘤的递送。为了评估关于肿瘤递送和生物分布模式的大量基因或化学修饰病毒,在体内进行研究将是有价值的可用的模型可以轻松筛选实验,比单克隆细胞系更复杂,并且可以在小型和大型动物的验证性研究之前用作平台方法。根据我们的数据,我们认为鸡绒毛尿囊膜 (CAM) 检测是一种快速且低成本的高通量肿瘤模型系统,用于体内分析溶瘤病毒。在这里,我们将 CAM 模型的建立、仔细表征和优化描述为体内用于评估溶瘤病毒的模型。我们已使用 5 型人类腺病毒 (HAdV-5) 作为验证示例,但相信该模型可用作复制许多不同病毒家族病毒的测试系统。我们表明 CAM 肿瘤模型能够进行瘤内和静脉内病毒给药,并且是分析相关病毒 - 宿主相互作用、生物分布模式和肿瘤靶向谱的可行且结论性的模型。
更新日期:2020-10-19
down
wechat
bug